Boehringer Ingelheim Signs Agreement With Hokkaido-Based Evec
This article was originally published in PharmAsia News
Major pharmaceutical company Boehringer Ingelheim of Germany signed a license agreement with Evec, a Hokkaido University-based biopharmaceutical venture company. According to the agreement, BI obtains worldwide exclusive rights on development and marketing for one of Evec's human therapeutic antibody programs. In return, Evec could receive up to €55 million in upfront and potential milestone payments. Evec will also receive royalties after the product's market launch. Established in 2003 and based in Sapporo, Hokkaido, Evec utilizes Epstein-Barr virus' lymphoproliferative. (Click here for more - Japanese language
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.